Beat on Revs and Profit, but stock down 4%. Why?
After the initial, very short pop, SAVE is now down $2.00 (over 4%)
I guess the revenue per seat - mile ratio which dropped must be the problem.
This stock does not seem ready to head to $60, more like $40
I'm long a few hundred shares, maybe will buy more if it gets down to the 40 range.
In today's announcement, the company authorized a new $1B buy back plan for the next 18 months.
The current market cap for URI is only 5.2 Billion.
Does this mean the company will buy back 20% of existing shares in the next year and a half?
Will EPS go up by 20%?
Today's presentation said the data showed that plasma levels of intact parathyroid hormone (iPTH) continued to fall as serum levels of 25-hydroxyvitamin D (25D) rose above 30 ng/mL, a level considered sufficient for CKD patients in published clinical practice guidelines. These data suggest that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought in order to control elevated iPTH.
It seems to me that this is important to Opko because Rayaldee raises this serum level. I didn't see any commentary on this presentation. I hope this isn't a step backwards in the upcoming product launch, but it seems to me that this is another indication of how much the new Rayaldee is needed.